The chair and several board members of Novo Nordisk are stepping down after a disagreement with the company's Foundation and controlling shareholder.
The rift has occurred over the fate of the board, and its comprising members, with the Novo Nordisk Foundation proposing that its current chair, Lars Rebien Sørensen, also become chair of the board of directors.
The Danish pharma giant, makers of weight loss and diabetes drug Wegovy, confirmed on Tuesday the current chair, Helge Lund, would be stepping down, alongside six other board members.
“The Board proposed a renewal focusing on addition of select, new competencies while also maintaining continuity, whereas the Board of the Foundation wanted a more extensive reconfiguration,” said Lund on the decision to walk away.
An Extraordinary General Meeting will be held on 14 November to determine the future of the board.
